Investor Presentation

30 Investor presentation First six months of 2022 Novo NordiskⓇ Pipeline supports significant growth opportunities across all four strategic focus areas PHASE 1 NN1147 - Insulin 147 and PCSK9i NN1845 - GSI NN1471 - Ideal Pump Insulin NN9041-DNA Immunotherapy NN9215 LA-GDF15 NN9838 Cagrisema NN6020 DCR-AUD PHASE 2 NN9388 Cagrisema NN9389 - FDC Sema - OW GIP NN9917 Oral 217 SGLT2i NN9838 Cagrilintide - NN9775 PYY 1875 analogue - NN7533 Eclipse NN9931 Gilead NASH - - NN9500 FGF-21 NASH NN6435 Oral PCSK9i NN6021 - Belcesiran - NN6019 NNC6019 ATTR Cardiomypathy PHASE 3 NN1535 Icosema NN9924 Oral Semaglutide 25 and 50 mg NN1436 - Insulin Icodec NN9932 Oral Semaglutide 50mg obesity NN9931 Semaglutide NASH NN6535 Semaglutide in AD NN6018 - Ziltivekimab - EX2020 Macimorelin, GHD¹ NN-7022 Nedosiran NN7415 Concizumab - NN7769 Mim8 (phase 2/3) Other PHASE 3 trials SOUL - Oral semaglutide 14.0 mg CVOT FOCUS Semaglutide 1.0 mg in diabetic retinopathy FLOW-Semaglutide 1.0 mg in chronic kidney disease STRIDE-Semaglutide 1.0 mg in peripheral arterial disease STEP Semaglutide 2.4mg in HFPEF SUBMITTED NN8640-Sogroya® - QW GHD2 APPROVED TresibaⓇ XultophyⓇ LevemirⓇ RyzodegⓇ NovoMixⓇ FiaspⓇ NovoRapidⓇ RybelsusⓇ OzempicⓇ4 VictozaⓇ WegovyⓇ4 SaxendaⓇ NovoSevenⓇ NovoEight® EsperoctⓇ NovoThirteenⓇ Refixia® SELECT Semaglutide 2.4mg in obese population NorditropinⓇ SogroyaⓇ5 Diabetes care Obesity care Rare blood disorders Rare endocrine disorders Other serious chronic diseases 1 Novo Nordisk only holds the commercial rights in North America; 2 Study conducted in growth hormone disorders; 3 Submitted in the EU and the US (Resubmitted on 28 May 2021); 4 includes sema 2.0 mg; 5 Approved in the EU, the US and Japan, for adult growth hormone disorder; PYY: Peptide YY; QW: Once-weekly; mAb: monocolonal antibody; GDF15: Growth differentiation factor 15; Sema: Semaglutide; FGF-21: Fibroblast growth factor 21; LAI: Long-acting insulin; GHD: Growth hormone disorder; GSI: Glucose Sensitive Insulin; HFPEF: heart failure with preserved ejection fraction; AD: Alzheimer's Disease; FDC; Fixed-dose combination; NASH: Nonalcoholic Steatohepatitis, Cagrilintide was denoted AM833 before NN Project IDs are pending for the assets Nedosiran, Belcesiran, DCR-AUD

View entire presentation